Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F3 | P13726 | 3/20 | 0.76 |
| ▸ | MAPT | P10636 | 6/20 | 0.69 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.69 |
| ▸ | MAOB | P27338 | 3/20 | 0.69 |
| ▸ | CYP1B1 | Q16678 | 3/20 | 0.69 |
| ▸ | MEN1 | O00255 | 3/20 | 0.69 |
| ▸ | MAOA | P21397 | 2/20 | 0.69 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.69 |
| ▸ | HSPD1 | P10809 | 2/20 | 0.69 |
| ▸ | HSPE1 | P61604 | 2/20 | 0.69 |
| ▸ | ALDH2 | P05091 | 1/20 | 0.69 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.69 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.69 |
| ▸ | RAB9A | P51151 | 5/20 | 0.67 |
| ▸ | ESR1 | P03372 | 1/20 | 0.65 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.65 |
| ▸ | CXCL12 | P48061 | 1/20 | 0.65 |
| ▸ | POLB | P06746 | 1/20 | 0.65 |
| ▸ | P4HB | P07237 | 3/20 | 0.64 |
| ▸ | CYP1A1 | P04798 | 2/20 | 0.64 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28700731 | 1.00 | F3 (0.76) | F3MAPTKMT2AMAOBCYP1B1 | |
| SCHEMBL31436374 | 0.93 | F3 (0.76) | F3MAPTKMT2AMAOBCYP1B1 | |
| SCHEMBL1603995 | 0.93 | F3 (0.76) | F3MAPTKMT2AMAOBCYP1B1 | |
| SCHEMBL6934854 | 0.89 | CYP1B1 (0.70) | F3MAPTMAOBCYP1B1CYP3A4 | |
| SCHEMBL6934856 | 0.89 | CYP1B1 (0.70) | F3MAPTMAOBCYP1B1CYP3A4 | |
| SCHEMBL25211913 | 0.87 | F3 (1.00) | F3MAPTKMT2AMAOBCYP1B1 | |
| 4,4'-Dihydroxychalcone SCHEMBL25202156 | 0.87 | F3 (1.00) | F3MAPTKMT2AMAOBCYP1B1 | |
| SCHEMBL25236411 | 0.87 | F3 (1.00) | F3MAPTKMT2AMAOBCYP1B1 | |
| SCHEMBL10703657 | 0.87 | F3 (1.00) | F3MAPTKMT2AMAOBCYP1B1 | |
| SCHEMBL25223420 | 0.87 | F3 (1.00) | F3MAPTKMT2AMAOBCYP1B1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8242144-B2 | Stilbenes and chalcones for the prevention and treatment of cardiovascular diseases | RESVERLOGIX CORP. (CA) | 2012-08-14 | — | — | US | disclosed |
| US-20110082176-A1 | Stilbenes and Chalcones for the Prevention and Treatment of Cardiovascular Diseases | RESVERLOGIX CORP. | 2011-04-07 | — | — | US | disclosed |
| US-7846915-B2 | Stilbenes and chalcones for the prevention and treatment of cardiovascular diseases | Resverlogix Corporation (CA) | 2010-12-07 | — | — | US | disclosed |
| US-20060205792-A1 | Stilbenes and chalcones for the prevention and treatment of cardiovascular diseases | HEPALINK (HONG KONG) LIMITED (HK) | 2006-09-14 | — | — | US | disclosed |
| WO-2006045010-A2 | STILBENES AND CHALCONES FOR THE PREVENTION AND TREATMENT OF CARDIOVASCULAR DISEASES | RESVERLOGIX CORP. (CA) | 2006-04-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060205792-A1 | Stilbenes and chalcones for the prevention and treatment of cardiovascular diseases | APOB, APOL1, HDLBP | F3 671/4885MAPT 2177/4885KMT2A 3632/4885 |
| US-20110082176-A1 | Stilbenes and Chalcones for the Prevention and Treatment of Cardiovascular Diseases | APOB, APOL1, HDLBP | F3 671/4885MAPT 2177/4885KMT2A 3632/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.